Evaluation of the evolution of patients with vitreous hemorrhage caused by proliferative diabetic retinopathy subjected to intravitreal injection of antivascular endothelial growth factor (bevacizumab)
Phase 3
Recruiting
- Conditions
- proliferative diabetic retinopathyvitreous hemorrhage
- Registration Number
- ACTRN12618000697280
- Lead Sponsor
- Hospital Oftalmológico de Sorocaba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bevacizumab's efficacy in proliferative diabetic retinopathy with vitreous hemorrhage?
How does intravitreal bevacizumab compare to standard-of-care treatments for vitreous hemorrhage in phase III trials?
Which biomarkers correlate with response to anti-VEGF therapy in patients with proliferative diabetic retinopathy?
What are the long-term adverse events associated with repeated intravitreal bevacizumab injections for vitreous hemorrhage?
Are combination therapies with anti-VEGF agents improving outcomes in proliferative diabetic retinopathy compared to monotherapy?